- Water for injection (WFI), and
- wherein the formulation has a pH of 6.8 +/- 0.3.

13. A liquid pharmaceutical formulation as described in any one of the preceding claims, for use in a method of treatment of infertility.

14. The pharmaceutical formulation for the use of claim 13, wherein the treatment is a treatment of ovulation induction (OI), assisted reproductive techniques (ART), and/or hypogonadotrophic hypogonadism in men.

15. A method for stabilization of a liquid pharmaceutical formulation, comprising hMG, which comprises the step of
    - Providing a sample of urine from a human woman,
    - Extracting hMG from the sample,
    - Compounding said extract with arginine and methionine, in amounts as defined in any of the preceding claims,
    - Optionally further adding phenol and polysorbate in amounts as defined in any of the preceding claims,
    - Adjusting the pH of the formulation to between 6.0 and 7.5,
    - wherein no additional buffer is added.

16. Use of a liquid pharmaceutical formulation as described in any one of claims 1-12, in the manufacture of a medicament for the treatment of infertility.

17. The use of claim 16, wherein the treatment is a treatment of ovulation induction (OI), assisted reproductive techniques (ART), and/or hypogonadotrophic hypogonadism in men.